FeesSafety
Pluang+

OpenAI cuts Astra model costs but it gives shorter, less cautious answers with more coding errors.

Protocol Fundamentals
19 Nov 2026, 04:10 WIB
Crypto Briefing
View Source
Bullish
OpenAI cuts Astra model costs but it gives shorter, less cautious answers with more coding errors.

OpenAI released GPT-6.2 Astra and Sol models with Astra aimed at complex professional tasks and Sol for everyday use. Astra's API pricing dropped 20%, and cached input costs fell 60%, making it cheaper for businesses. However, Astra now provides shorter, less structured answers and admits uncertainty less, leading to a doubling in coding omission errors from 11% to 22%. This trade-off means lower costs but potentially higher risks for developers relying on Astra's guidance. The models are currently available only via ChatGPT Work, Codex, and API, targeting professional users.

OpenAI's GPT-6.2 Astra and Sol models are the subject, with Pluang market data as context. As of Nov 19, 2026 08:21 WIB, out of 50 major cryptocurrencies priced on Pluang, 8 rose and 40 fell. Notable movers include CRV at Rp3.622 with a 5.01% decline and a Pluang order activity of 58% Sell / 42% Buy, CAKE at Rp28.597 down 4.64% with 77% Sell activity, and ZIL at Rp18 up 4.45% with 75% Buy activity. The most notable figure is CAKE's 77% sell order activity.

More News

Anthropic plans IPO to fund AI-driven bioscience, with potential future ties to Ginkgo Bioworks' lab automation.

Anthropic plans IPO to fund AI-driven bioscience, with potential future ties to Ginkgo Bioworks' lab automation.

Anthropic is set to go public on November 19, raising tens of billions to boost its AI capabilities in bioscience, focusing on lab automation and robotics. Ginkgo Bioworks, a leader in automated biotech labs, collaborates with OpenAI but has no curre...

Market News
Bullish
58 minutes ago
BellRing shares jump 24% on strong sales and upbeat earnings forecast

BellRing shares jump 24% on strong sales and upbeat earnings forecast

BellRing Brands saw a 24% surge in its stock price after reporting a 7% increase in net sales to $692 million for fiscal 2026 Q4, driven by strong demand for its high-protein Premier Protein shakes and new product launches like Sparkling Protein Soda...

Company Fundamentals
Bullish
1 hour ago
Analyst cuts Peabody Energy price target by nearly 30% but keeps buy rating.

Analyst cuts Peabody Energy price target by nearly 30% but keeps buy rating.

Freedom Broker analyst Vitaly Kononov lowered Peabody Energy's price target from $30 to $22 per share, citing reduced production outlooks at its key Centurion coal mine and vulnerability in coal prices. Despite the significant cut, he maintained a bu...

Analyst Insights
Bearish
1 hour ago
Micron's strong growth and rising stock price hint at a possible future stock split.

Micron's strong growth and rising stock price hint at a possible future stock split.

Micron Technology is showing strong financial growth, driven by its crucial role in AI infrastructure and multiyear deals with key tech companies. The company recently beat revenue expectations with a 379% year-over-year increase and projects even be...

Company Fundamentals
Bullish
2 hours ago
FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

FDA approves Livsayis™, first siRNA therapy for generalized myasthenia gravis, offering new treatment option.

The FDA has approved Livsayis™ (cemdisiran), the first and only siRNA therapy for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive. This subcutaneous treatment, administered four times a year, targ...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App